Literature DB >> 315849

Suppression of immunoglobulin synthesis by monocytes in health and in patients with systemic lupus erythematosus.

A H Laughter, M D Lidsky, J J Twomey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 315849     DOI: 10.1016/0090-1229(79)90095-3

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


× No keyword cloud information.
  7 in total

1.  Monocyte-mediated suppression of anti-DNA antibody production in healthy subjects.

Authors:  M Okawa-Takatsuji; S Aotsuka; S Uwatoko; M Kinoshita; R Yokohari
Journal:  Clin Exp Immunol       Date:  1989-09       Impact factor: 4.330

2.  Accessory cell activity of monocytes in anti-DNA antibody production in systemic lupus erythematosus.

Authors:  T Sasaki; S Shibata; Y Hirabayashi; Y Sekiguchi; K Yoshinaga
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

3.  Synthesis of antibodies to hepatitis B virus by cultured lymphocytes from chronic hepatitis B surface antigen carriers.

Authors:  G M Dusheiko; J H Hoofnagle; W G Cooksley; S P James; E A Jones
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

4.  Paraproteinaemia: use of idiotypic determinants as specific markers for tumour activity.

Authors:  M A King; J Vivianwells
Journal:  Clin Exp Immunol       Date:  1981-09       Impact factor: 4.330

5.  Spectrum of immunodeficiencies with Hodgkin's disease.

Authors:  J J Twomey; A H Laughter; L Rice; R Ford
Journal:  J Clin Invest       Date:  1980-10       Impact factor: 14.808

6.  A comparison of the regulatory effects of human monocytes, pulmonary alveolar macrophages (PAMs) and spleen macrophages upon lymphocyte responses.

Authors:  J J Twomey; A Laughter; M F Brown
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

7.  Monocyte suppression of Fusobacterium nucleatum-induced human polyclonal B-lymphocyte activation.

Authors:  D F Mangan; T Won; D E Lopatin
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.